Share on StockTwits

Pernix Therapeutics Holdings (NYSE:PTX) major shareholder James Edward Jr. Smith unloaded 30,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $4.68, for a total transaction of $140,400.00. Following the transaction, the insider now directly owns 4,382,704 shares of the company’s stock, valued at approximately $20,511,055. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Pernix Therapeutics Holdings (NYSE:PTX) traded down 3.74% during mid-day trading on Thursday, hitting $4.63. The stock had a trading volume of 294,326 shares. Pernix Therapeutics Holdings has a 52-week low of $1.68 and a 52-week high of $6.02. The stock has a 50-day moving average of $4.88 and a 200-day moving average of $3.16. The company’s market cap is $172.9 million.

Pernix Therapeutics Holdings (NYSE:PTX) last announced its earnings results on Monday, March 17th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.05. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.82 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. On average, analysts predict that Pernix Therapeutics Holdings will post $0.01 earnings per share for the current fiscal year.

A number of research firms have recently commented on PTX. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Pernix Therapeutics Holdings in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $3.25.

Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.